{
    "id": 5567,
    "fullName": "ABL1 E255K",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 E255K lies within the protein kinase domain of the Abl1 protein (UniProt.org). E255K demonstrates catalytic efficiency (kcat/km) similar to wild-type Abl1 in an in vitro assay (PMID: 30684523), results in increased autophosphorylation and Stat5 phosphorylation in the context of BCR-ABL1, and has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL (PMID: 15194504), but has not been fully characterized and therefore, its effect on Abl1 protein function is unknown.",
            "references": [
                {
                    "id": 2626,
                    "pubMedId": 15194504,
                    "title": "The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15194504"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 14163,
                    "pubMedId": 30684523,
                    "title": "The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30684523"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "E255K",
    "createDate": "04/30/2015",
    "updateDate": "02/05/2020",
    "referenceTranscriptCoordinates": {
        "id": 119147,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130862976G>A",
        "cDna": "c.763G>A",
        "protein": "p.E255K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2108,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells expressing BCR-ABL E255K demonstrated resistance to Gleevec (imatinib) (PMID: 15194504).",
            "molecularProfile": {
                "id": 5391,
                "profileName": "BCR - ABL1 ABL1 E255K"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2626,
                    "pubMedId": 15194504,
                    "title": "The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15194504"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20133,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 E255K (NCCN.org).",
            "molecularProfile": {
                "id": 5391,
                "profileName": "BCR - ABL1 ABL1 E255K"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18913,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 E255K (NCCN.org).",
            "molecularProfile": {
                "id": 5391,
                "profileName": "BCR - ABL1 ABL1 E255K"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2107,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited cell growth of transformed cells expressing BCR-ABL1 E255K in culture and in cell line xenograft models (PMID: 16105974).",
            "molecularProfile": {
                "id": 5391,
                "profileName": "BCR - ABL1 ABL1 E255K"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2628,
                    "pubMedId": 16105974,
                    "title": "NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16105974"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6250,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 61.5% (8/13) of chronic myeloid leukemia patients harboring ABL1 E255K in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 5391,
                "profileName": "BCR - ABL1 ABL1 E255K"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10587,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the allosteric inhibitor Asciminib (ABL001) inhibited growth of transformed cells expressing the catalytic-site-resistant mutation ABL1 E255K in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 5391,
                "profileName": "BCR - ABL1 ABL1 E255K"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11925,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 E255K in the context of BCR-ABL1 was associated with resistance to Gleevec (imatinib) in patients with BCR-ABL1-positive leukemia, and resistance was confirmed in a kinase assay (PMID: 12399961).",
            "molecularProfile": {
                "id": 5391,
                "profileName": "BCR - ABL1 ABL1 E255K"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9903,
                    "pubMedId": 12399961,
                    "title": "Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12399961"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12901,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BCR-ABL1 and ABL1 E255K demonstrated a decreased response to treatment with AP23464 in culture compared to cells co-expressing BCR-ABL1 and other ABL1 mutations such as ABL1 Q252H and ABL1 Y253F (PMID: 15256422).",
            "molecularProfile": {
                "id": 5391,
                "profileName": "BCR - ABL1 ABL1 E255K"
            },
            "therapy": {
                "id": 2593,
                "therapyName": "AP23464",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2591,
                    "pubMedId": 15256422,
                    "title": "Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15256422"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7980,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment did not result in clinical response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 F359V (82%), T315I (3%), and F359V/E255K (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26124,
                "profileName": "BCR - ABL1 ABL1 E255K ABL1 T315I ABL1 F359V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8335,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Tasigna (nilotinib) synergistically induced apoptosis in leukemia cells derived from Tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia patients harboring ABL1 E255K and T315I in the context of BCR-ABL1, and expressing Bcl2 in culture (PMID: 27605552).",
            "molecularProfile": {
                "id": 26231,
                "profileName": "BCR - ABL1 ABL1 E255K ABL1 T315I BCL2 pos"
            },
            "therapy": {
                "id": 4707,
                "therapyName": "Nilotinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6621,
                    "pubMedId": 27605552,
                    "title": "Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27605552"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 5390,
            "profileName": "ABL1 E255K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5391,
            "profileName": "BCR - ABL1 ABL1 E255K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23151,
            "profileName": "BCR - ABL1 ABL1 E255K ABL1 F359V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26124,
            "profileName": "BCR - ABL1 ABL1 E255K ABL1 T315I ABL1 F359V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26231,
            "profileName": "BCR - ABL1 ABL1 E255K ABL1 T315I BCL2 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119146,
            "transcript": "NM_007313",
            "gDna": "chr9:g.130862919G>A",
            "cDna": "c.763G>A",
            "protein": "p.E255K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 119147,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130862976G>A",
            "cDna": "c.763G>A",
            "protein": "p.E255K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}